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Increasing survival of motor neuron 2, centromeric (SMN2) exon 7 inclusion to express more full-length SMN
protein in motor neurons is a promising approach to treat spinal muscular atrophy (SMA), a genetic neurode-
generative disease. Previously, we identified a potent 29-O-(2-methoxyethyl) (MOE) phosphorothioate-modified
antisense oligonucleotide (ASO) that blocks an SMN2 intronic splicing silencer element and efficiently promotes
exon 7 inclusion in transgenic mouse peripheral tissues after systemic administration. Here we address its efficacy
in the spinal cord—a prerequisite for disease treatment—and its ability to rescue a mild SMA mouse model that
develops tail and ear necrosis, resembling the distal tissue necrosis reported in some SMA infants. Using a micro-
osmotic pump, we directly infused the ASO into a lateral cerebral ventricle in adult mice expressing a human
SMN2 transgene; the ASO gave a robust and long-lasting increase in SMN2 exon 7 inclusion measured at both the
mRNA and protein levels in spinal cord motor neurons. A single embryonic or neonatal intracerebroventricular
ASO injection strikingly rescued the tail and ear necrosis in SMA mice. We conclude that this MOE ASO is
a promising drug candidate for SMA therapy, and, more generally, that ASOs can be used to efficiently redirect
alternative splicing of target genes in the CNS.
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Spinal muscular atrophy (SMA) is an autosomal reces-
sive neuromuscular disease caused by progressive loss of
a-motor neurons in the anterior horn of the spinal cord.
There are three types of childhood-onset SMA, based on
the severity and the time of onset: Type I is most severe,
and type III is a mild form (Munsat and Davies 1992;
Crawford 2003; Russman 2007; Wang et al. 2007). Type
IV is adult-onset SMA. There are currently no effective
therapies for SMA.
Reduced expression of functional survival motor neu-
ron (SMN) protein is responsible for SMA (Lefebvre et al.
1995, 1997; Coovert et al. 1997). SMN is expressed from
two linked paralogous genes: Survival of motor neuron 1,
telomeric (SMN1) and Survival of motor neuron 2, cen-
tromeric (SMN2). SMN is localized mainly in the cyto-
plasm and nuclear gems in all cells (Liu and Dreyfuss
1996), as well as in motor neuron axons (Zhang et al.
2006), and its best-understood function is mediating the
assembly of spliceosomal small nuclear ribonucleopro-
tein particles (snRNPs) (Meister et al. 2001; Pellizzoni
et al. 2002; Kolb et al. 2007). In SMA patients, SMN1 is
homozygously deleted or mutated; however, the presence
of at least one copy of SMN2 allows viability, although it
cannot fully compensate for SMN1 loss of function
because of an altered pattern of splicing in SMN2.
Mice have only one SMN1 ortholog, Smn. Human SMN2
can rescue the embryonic lethality of Smn/ mice, and
these transgenic mice display SMA-like phenotypes to
varying degrees, depending on the transgene’s copy number
and expression levels, and the nature of the deletion alleles
(Schrank et al. 1997; Hsieh-Li et al. 2000; Monani et al.
2000). The defects in snRNP assembly in SMA mouse
tissues correlate with phenotypic severity (Gabanella et al.
2007). The phenotypes can include muscle weakness, pre-
mature death, reduced body size andweight, and/or tail and
ear necrosis. Mice with a severe SMA phenotype resem-
bling human type I SMA survive <1–2 wk, and typically
have two copies of the SMN2 transgene. So-called D7 mice
have also been generated that express high levels of human
cDNA lacking exon 7, in addition to carrying two copies of
the SMN2 transgene in a homozygous-null mouse Smn
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background (Le et al. 2005). Mice that survive and breed
normally, but develop tail and ear necrosis, are classified as
type III (Hsieh-Li et al. 2000); they have four copies of the
SMN2 transgene, and a homozygous replacement of exon
7 and some of flanking intron sequences of themouse Smn
gene with an HPRTcassette (Hsieh-Li et al. 2000; Gogliotti
et al. 2010). Tail and ear necrosis have also been observed in
type I SMA and D7 mice after various treatments that
extended their survival (Narver et al. 2008; Meyer et al.
2009; Foust et al. 2010; Passini et al. 2010; Riessland et al.
2010). Consistent with these observations in SMA mouse
models, distal necrosis associated with anomalous vascular
perfusion was reported recently as a clinical feature in two
infants with type I SMA (Araujo Ade et al. 2009). These and
other mouse SMA models are invaluable tools for validat-
ing and improving the efficacy of various lead compounds
under development as SMA drugs.
Various approaches have been undertaken to treat SMA
(Lunn and Wang 2008). Recently, it was shown that AAV
(adeno-associated virus)-mediated SMN overexpression
rescued the severe phenotype of D7 SMAmice (Foust et al.
2010; Passini et al. 2010). SMN2 targeted drug screens to
correct SMN2 splicing and enhance SMN2 transcription,
translation, or stability have been an important theme in
therapeutics development for SMA. A number of com-
pounds, such as histone deacetylase (HDAC) inhibitors,
have been identified that can significantly increase cellular
SMN protein levels, and some of them are currently in
clinical trials (Lunn and Wang 2008). Several antisense
approaches have been undertaken to correct SMN2 splic-
ing, such as blocking exonic splicing silencers (EESs)/
intronic splicing silencers (ISSs) or the intron 7–exon 8
junction, and using bifunctional or chimeric antisense
oligonucleotides (ASOs), or trans-splicing RNAs (Lim
and Hertel 2001; Miyajima et al. 2002; Cartegni and
Krainer 2003; Skordis et al. 2003; Madocsai et al. 2005;
Singh et al. 2006; Coady et al. 2007; Geib and Hertel 2009);
some of these strategies have shown beneficial effects in
SMA model mice (Baughan et al. 2009; Meyer et al. 2009;
Coady and Lorson 2010).
Singh et al. (2006) discovered an intron 7 ISS in the
human SMN1/2 genes, termed ISS-N1; ASOs that block
ISS-N1 strongly enhance SMN2 exon 7 inclusion in cul-
tured patient fibroblasts. Using an ASO-tilingmethod, we
systematically analyzed the elements in and flanking
SMN2 exon 7 that modulate exon 7 inclusion in cell-free
splicing and in cultured cells (Hua et al. 2007, 2008). By
comparing hundreds of ASOs that target various splicing
silencers in exon 7 and both flanking introns (Hua et al.
2008; data not shown), we identified an optimal 18mer
29-O-(2-methoxyethyl) (MOE) ASO (#10–27) that targets
ISS-N1 in intron 7. The lead ASO also promotes efficient
SMN2 exon 7 inclusion in the liver and kidneys of trans-
genic mice after systemic administration, but not in the
spinal cord (Hua et al. 2008), owing to a lack of distribution
across an intact blood–brain barrier (BBB) (Geary et al. 2003).
In a recent study, Williams et al. (2009) directly de-
livered a 29-O-methyl (29-OMe) phosphorothioate (P = S)
ASO targeting ISS-N1 into the CNS by repeated neonatal
intracerebroventricular (ICV) injections in the D7 mouse
model. They reported a small increase in SMN protein
and full-length (FL) SMN2 mRNA in the spinal cord, as
well as improvements in weight gain and the righting
response (Williams et al. 2009). However, only one dosing
regimen was tested, an effect on survival was not assessed,
and several ASO-treated and control mice died prema-
turely (Williams et al. 2009). In addition, the expression of
prespliced mRNA from the human D7 cDNA in this strain
makes it more challenging to accurately measure changes
in the relative levels of exon 7 inclusion and skipping in
mRNA expressed from the SMN2 transgene.
In the present study, we thoroughly investigated and
optimized the in vivo efficacy of ISS-N1-directed ASOs
in the CNS, including validation of the mechanism
of action, pharmacokinetic (PK) and pharmacodynamic
(PD) profiles, and effects of oligonucleotide size and base
modifications, as well as method of delivery and dosing
regimen. To avoid survival issues in mice with very short
life spans, and to facilitate accurate measurements of
mRNA splicing as well as of the long-term efficacy and
metabolism of the ASOs, we initially characterized our
lead MOE ASO, delivered by ICV infusion, in the CNS of
adult mice of a type III SMA model strain (Hsieh-Li et al.
2000). The ASO promoted very efficient expression of FL
SMN2 mRNA and protein in the spinal cord, including
motor neurons. Remarkably, the effect persisted for several
months after ICV infusion for only 7 d. The favorable PK/
PD profile of the ASO allowed us to test its therapeutic
efficacy by using a single embryonic or neonate ICV in-
jection in the mild SMA mouse model. We show that the
ASO can successfully rescue the distal tissue necrosis
phenotype in the type III mousemodel, demonstrating that
this ASO is a promising drug candidate for SMA therapy.
Results
ASO administration into adult mouse spinal cord
To analyze the effects of ASO 10–27 in mouse CNS, we
used ICV infusion to deliver the ASO into the cerebro-
spinal fluid (CSF). Controlled delivery was achieved by
means of a micro-osmotic pump implanted subcutane-
ously and connected through a catheter to a cannula
surgically implanted into the right lateral ventricle, a pro-
cedure suitable for adult mice. ASO solution was infused
into the CSF for 7 d at 0.5 mL/ per hour, and tissues were
analyzed on the eighth day. We first performed a dose
response study with type III SMA heterozygous mice
(Smn+/; SMN2+/+) with four copies of an SMN2 trans-
gene. Radioactive RT–PCR of thoracic spinal cord RNA
with human-specific primers demonstrated a dose-
dependent increase in exon 7 inclusion (Fig. 1A,B). After
ASO infusion at 10 mg per day, exon 7 inclusion in the
SMN2 transgene mRNA increased to >30%, compared
with ;10% in saline-treated mice, and ;90% inclusion
was achieved at a dose of 50 mg per day. The effect
plateaued at 100 mg per day, which gave ;96% exon 7
inclusion. RNA samples were also analyzed for SMN2
splicing by real-time RT–PCR with separate primer pairs
for the inclusion and skipping isoforms, with consistent
results (Fig. 1C).
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To establish that the increase in SMN2 FL mRNA in the
spinal cord results in increased hSMN protein, we per-
formed Western blots with a new human SMN-specific
monoclonal antibody (mAb) (SMN-KH) (Supplemental Fig.
S1), and a commercial mAb (SMN-BD) that recognizes
both human and mouse SMN. ASO treatment resulted in
a clear dose-dependent increase in hSMN protein levels,
paralleling that of FL SMN2 mRNA levels (Supplemental
Fig. S2). A 4.3-fold mean increase in hSMN protein levels
was observed after treatment with 50 mg of ASO per day
(Fig. 1D). Thoracic spinal cord samples from several type III
SMA homozygous mice (Smn/; SMN2+/+) treated with
$50 mg of ASO per day for 7 d also showed a robust hSMN
protein level increase. In the presence of the ASO, the
transgene expressed higher levels of protein than the
endogenous mouse Smn gene, and the hSMN protein lev-
els in treated homozygotes were much higher than the
total SMN levels in untreated heterozygotes (Fig. 1D;
Supplemental Fig. S2).
In addition, mRNA and protein samples from the brain
cortex of the samemice also exhibited strong increases in
both FL SMN2 transcripts and hSMN protein levels
(Supplemental Fig. S3). These data clearly demonstrate
that ASO 10–27 delivered into the CNS by direct admin-
istration into the CSF rescues splicing of the SMN2
transgene, resulting in robust FL SMN protein increase.
Spinal cord immunostaining of ASO and hSMN
protein after ICV infusion
We next asked how these ASOs distribute in cells in the
spinal cord, and whether the increase in SMN protein can
be detected in individual motor neurons by immunohis-
tochemistry. To this end, thoracic spinal cord tissues
were fixed and sectioned. The sections were stained with
either a polyclonal antibody (pAb) that specifically rec-
ognizes phosphorothioate-modified ASOs (Butler et al.
1997), or with SMN-KHmAb (Fig. 2A). ASO was detected
in both the cytoplasm and the nucleus of individual
neurons in a dose-dependent manner, with the majority
of the ASO accumulating in the nucleus.Moreover, as the
ASO dose increased, hSMN protein staining likewise
became stronger in both compartments. ASO infusion
at $50 mg per day for 7 d resulted in many more gems,
compared with the controls. We further performed coim-
munofluorescencewith thoracic spinal cord sections using
SMN-KHmAb and a pAb recognizing choline acetyltrans-
ferase (ChAT), a motor neuron marker. We observed a pro-
nounced increase in both the SMN signal and the number
of gems in motor neurons after the 7-d ICV infusion at 50
mg per day (Fig. 2B; Supplemental Fig. S4). Gem number is
a positive indicator of SMN protein levels (Coovert et al.
1997), and thus these data confirm and extend the above
RT–PCR and Western blotting analyses.
ASO effects throughout the spinal cord and persistence
of the effect
When ASOs are infused into the lateral ventricles and
travel down to distal neuronal tissues following the CSF
flow, neurons in the upper spinal regions may take up the
ASOs more efficiently than the lower regions. To address
this issue, we compared cervical, thoracic, and lumbar
spinal cord RNA samples from mice treated with either
25 or 50 mg of ASO 10–27 per day for 7 d, or with a
mismatch MOE ASO as a control. At the lower dose, we
observed significantly lower levels of exon 7 inclusion in
the lumbar region than in the other two regions (Fig.
3A,C). However, at 50 mg per day, we did not observe
significant differences among different regions of the
spinal cord, indicating that this dose is sufficient for the
distal spinal cord to accumulate a comparable amount of
ASOs as the proximal spinal cord (Fig. 3A,C). Furthermore,
this dose of ASOs probably results in maximal occupancy
of pre-mRNA-binding sites in all spinal cord segments.
Figure 1. Dose response study of ASO 10–27 in the spinal cord
after ICV infusion in adult mice. ASO 10–27 at the indicated
daily doses was infused for 7 d into the right cerebral lateral
ventricle of type III SMA heterozygous mice. On day 8, mice
were euthanized. (A) Thoracic spinal cord RNA samples were
analyzed by radioactive RT–PCR. FL and D7 represent full-
length and exon 7-skipped SMN2 transcripts, respectively; ‘‘%
incl’’ is the percentage of the FL spliced mRNA in total SMN2
transcripts. Four representative samples are shown for each
dose. (B) Quantitation of the data in A plus unpublished data (n =
5) (Y Hua and AR Krainer, unpubl.). Error bars represent standard
deviations (SD). (C) Quantitation by real-time RT–PCR. Both the
FL mRNA (+exon 7) and exon 7-skipped mRNA (exon 7) (n = 5)
were normalized with GAPDH, and the data were further
normalized to the level of the corresponding transcript in the
saline-treated controls (dose, 0 mg per day). (D) Thoracic spinal
cord protein samples obtained from four heterozygotes (the same
mice as in A) and four additional homozygotes, treated with
either saline or 50 mg per day of ASO, were analyzed by Western
blotting with antibodies SMN-KH (hSMN) or SMN-BD (total
SMN); b-tubulin was used as a loading control. Histograms on
the right show the protein quantitation.
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To determine the duration of action and tissue half-life
of the ASO, heterozygous type III SMAmice were treated
with 50 mg of ASO per day for 7 d by ICV infusion, and the
animals were sacrificed at various times after infusion for
up to 6 mo (Fig. 3B,D). Saline and mismatch ASO-treated
mice were used as controls, and showed a constant level
of ;10% exon 7 inclusion in the spinal cord (Fig. 3B; data
not shown). Remarkably, RT–PCR analysis showed that
the ASO still promoted ;90% SMN2 exon 7 inclusion
half a year after completing the 7-d treatment, suggesting
that this ASO is extremely stable in CNS tissues. Impor-
tantly, at all of the doses tested, the mice showed no signs
of toxicity throughout the time-course experiment. We
measured the ASO concentration in spinal cord tissue by
capillary gel electrophoresis and observed no reduction in
tissue concentration over a 2-mo period (Supplemental
Fig. S5). Although the very long half-life of the ASO in
mouse spinal cord tissue is striking, it was not unex-
pected, given that nuclease activity in neuronal tissue is
lower than in peripheral tissues (Whitesell et al. 1993),
and that the uniform MOE ASO is less susceptible to
endonucleases than traditional MOE gapmers.
ICV infusion of MOE ASO does not lead
to CNS inflammation
Because prolonged inflammation is associated with many
neurodegenerative diseases (Glass et al. 2010), we tested
whether the MOE ASO induces inflammation in the
mouse CNS. We compared the MOE ASO with the
29-OMe ASO that was used by Williams et al. (2009)
and Singh et al. (2006). The mismatch MOE ASO was
used as a control. Two days after 7-d ICV infusion of each
ASO at different doses in type III SMAmice, we examined
the expression of allograft inflammatory factor-1 (Aif1) in
both the brain and the lumbar spinal cord using real-time
RT–PCR. AIF1 is a marker of monocyte/microglial acti-
vation, and plays an important role in the immune
response (Yang et al. 2005). We observed no increase of
Aif1 mRNA level in the brain after the treatment of the
MOEASO at various concentrations. In the lumbar spinal
cord, there was a 20% increase in Aif1mRNA expression
at only the highest dose of MOE ASO (100 mg per day; P =
0.01) (Fig. 4). After treatment with the mismatch ASO,
Aif1 displayed a similar expression pattern, with slight
variations, as that in the MOE ASO-treated brain and
spinal-cord samples. In contrast, after treatment with the
29-OMe ASO at 10 mg per day, we observed a 1.8-fold
increase in Aif1 mRNA expression. At the highest dose
tested, the 29-OMe ASO resulted in a 3.3-fold and 1.8-fold
increase in Aif1 mRNA expression in the lumbar spinal
cord and the brain, respectively.
We also examined the effect of the three ASOs on
splicing of SMN2. RNA samples from the brain and the
lumbar spinal cordwere analyzed by real-time RT–PCR, as
above. Surprisingly, the 29-OMe ASO had no stimulatory
effect on SMN2 exon 7 inclusion, similar to the mismatch
control ASO, whereas the MOE ASO showed the same
potent stimulatory effect on SMN2 exon 7 splicing as
described above (Supplemental Fig. S6). Based on these
data, we conclude that the MOE ASO is a safer and much
more effective drug candidate than the 29-OMe ASO.
Figure 2. Detection of ASO 10–27 and hSMN protein
in spinal cord by immunostaining after ICV infusion.
(A) Thoracic spinal cord samples isolated 1 d after 7-
d ICV infusion of saline or ASO 10–27 at the indicated
daily doses were analyzed by immunohistochemistry
with a pAb that specifically recognizes the phosphor-
othioate backbone in ASOs, or with SMN-KH mAb
specific for human SMN. Nuclei were counterstained
with DAPI. (B) Confocal immunofluorescence images of
thoracic spinal cord double-labeled with SMN-KHmouse
mAb and anti-ChAT rabbit pAb, followed by incubation
with goat Alexa fluor 488 anti-mouse and Alexa fluor 568
anti-rabbit secondary antibodies. Bars, 25 mm.
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Embryonic ICV administration
We next sought to determine whether the MOE ASO
could rescue the SMA phenotype in mice. Type III SMA
mice display no muscle weakness, but have progressive
tail necrosis beginning at ;3 wk postnatally, and ear
necrosis at ;4–5 wk; they lose the tail completely in
5–6 wk, or are left with a short stub of dead tissue for
several days, in addition to gradually losing most of their
ears (Hsieh-Li et al. 2000; data not shown). To prevent or
delay the onset of necrosis in type III SMA mice, it is
necessary to treat them as early as possible. Therefore,
instead of the ICV infusion procedure, which is only
suitable for adult mice, and in light of the very long
half-life of the MOE ASO in the CNS, we used ICV
injection in embryos. We transiently exteriorized the
uterus of pregnant females at approximately embryonic
day 15 (E15), and used a glass capillary to inject the MOE
ASO as a single 2-mL dose into a brain lateral ventricle of
individual embryos.
We performed a dose response study in embryos from
crosses between heterozygous mice to measure how
much ASO is required to promote SMN2 exon 7 inclu-
sion, using single doses ranging from 0 to 20 mg in saline.
The ASO effects were assayed at postnatal day 7 (P7).
RT–PCR analysis of the lumbar spinal cord samples
revealed that 2.5 mg and 5 mg of the ASO induced 62%
and 77% exon 7 inclusion, respectively, whereas saline-
treated controls showed only 11% inclusion (Fig. 5A).
Doses of 10 and 20 mg both resulted in an average of 88%
exon 7 inclusion (Fig. 5A), indicating that the maximal
Figure 3. RT–PCR analysis of SMN2 splicing in different
regions of the spinal cord, and duration of action of ICV-infused
ASO 10–27. (A) Total RNA samples isolated from the cervical
(C), thoracic (T), or lumbar (L) spinal cord of mice treated by 7-d
ICV infusion with the indicated daily doses of ASO 10–27 or a six-
mismatch control ASO were analyzed by radioactive RT–PCR as
in Figure 1. Representative triplicate samples out of four mice for
each dose are shown. (B) After a 7-d ICV infusion of type III SMA
model heterozygous mice at 50 mg per day, total RNA samples
were prepared from thoracic spinal cord isolated at the indicated
time points (0 indicates 1 d after ICV infusion) and analyzed by
radioactive RT–PCR. (Con) Saline-treated controls. Representa-
tive triplicate samples from four to five mice for each time point
are shown. (C) Quantitation of SMN2 splicing in different regions
of the spinal cord. An asterisk (*) indicates a significantly lower
percentage of exon 7 inclusion in the lumbar than in the cervical
region (P = 0.045, n = 4, two-tailed paired Student’s t-test) and
thoracic regions (P = 0.031, n = 4). (D) Quantitation of the
duration-of-action data (n = 4-5). For all of the time points, the
difference from the control was highly significant (P # 9.3 3
109, two-tailed Student’s t-test). Error bars, SD.
Figure 4. 29-OMe but not MOE ASO induces an increase in
Aif1 expression, a marker of microglial activation. The MOE
ASO (MOE), a six-mismatch ASO (Mismatch), and the 29-OMe
ASO (29-OMe) (for sequences, see the Materials and Methods)
were delivered into the CNS of heterozygous type III SMA mice
by ICV infusion for 7 d at the indicated doses (n = 5 for all doses,
except for the 29-OMe treatment at 100 mg per day, for which two
mice died prematurely). On day 9, mice were euthanized, and the
whole brain (A) and lumbar spinal cord (B) were collected for total
RNA extraction. Aif1 mRNA levels were analyzed by real-time
RT–PCR with specific primers and normalized to GAPDH
mRNA. The data were further normalized to the saline controls
(dose, 0 mg per day, white bars). MOE ASO gave no increase of
Aif1 expression in the brain, and a 1.2-fold increase at only the
highest dose (100 mg per day) in the lumbar spinal cord (P = 0.01).
29-OMe ASO caused a large increase in Aif1mRNA levels at doses
$10 mg per day in the spinal cord, and at doses of 100 mg per day in
the brain. Error bars represent standard deviations. (*) P < 0.05; (**)
P < 0.01; (***) P < 0.001, compared with the saline controls.
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effect of the ASO was achieved at these doses when
measured in P7 neonates. The ASO effects after a single
embryonic injection were also assayed at P30; we ob-
served lower but still highly significant levels of exon 7
inclusion, compared with samples analyzed at P7 (Fig. 5B;
Supplemental Fig. S7A). This is an expected result for
a single embryonic injection because, with the increase in
body size and cell proliferation, the effective concentra-
tion of ASO will be reduced. We also compared RNA
samples from different spinal cord regions of mice
injected with 5 mg of ASO (below saturation at P7) and
10 mg of ASO (saturated at P7). At the lower dose, there
was slightly but significantly less exon 7 inclusion in the
lumbar spinal cord than in the other regions (Fig. 5C;
Supplemental Fig. S7B). We also tested 30 mg of ASO for
embryonic ICV injection; however, we observed a signif-
icant increase in fetal mortality at this dose.
Rescue of tail and ear necrosis in type III SMA mice
Based on the above dose response study with embryonic
ICV injection, we chose doses of 10 and 20 mg for thera-
peutic trials in mice. We set up crosses between Smn/;
SMN2+/+ homozygotes, such that all of the offspring were
phenotypically SMA type III. ASO solution (2mL) was again
injected ICV into individual embryos at E15, and, after
birth, the tail length of each treated pup was measured
weekly until 12 wk of age. Remarkably, the treatment
rescued both the tail and ear necrosis (Fig. 6A,C). Mice
treated with 20 mg of ASO showed no sign of necrosis and
had intact tails at 2 mo, whereas saline-treated, mismatch
ASO-treated (data not shown), or untreated (data not
Figure 5. Dose response study of ASO 10–27 in the lumbar
spinal cord after a single embryonic ICV injection. Using a glass
micropipette, 2 mL of ASO 10–27 was injected into a cerebral
lateral ventricle of individual embryos at approximately E15
(Smn+/ or Smn/; SMN2+/+) at the indicated doses. (A) The
effect of ASO 10–27 on SMN2 splicing was assayed at P7. Total
RNA isolated from the lumbar spinal cord was analyzed by
radioactive RT–PCR as in Figure 1. Three representative samples
from four to five treated mice are shown. (B) Quantitation of the
dose response radioactive RT–PCR data from lumbar spinal cords
obtained at P7 or P30 (n = 4–5). For all of the doses, the difference
between P7 and P30 was significant (P # 0.02, two-tailed
Student’s t-test). (C) Quantitation of the effects of ASO 10–27
in different spinal cord regions in P7 neonates; two doses (5 and
10 mg) were chosen for comparison. An asterisk (*) indicates
a significantly lower percentage of exon 7 inclusion in the lumbar
spinal cord than in the cervical (P = 0.017, n = 4, two-tailed paired
Student’s t-test) and thoracic (P = 0.016, n = 4) regions.
Figure 6. Phenotypic rescue of type III SMA mice (Smn/;
SMN2+/+) after a single embryonic ICV injection of ASO 10–27.
(A) Tail lengths were measured from P7 to 12 wk old, at weekly
intervals. E15 embryos were injected with saline vehicle (n = 10)
or 10 mg (n = 17) (ASO-10) or 20 mg (n = 11) (ASO-20) of ASO 10–
27 in a volume of 2 mL. Normal mice (Smn+/+ or Smn+/) were
used as positive controls (n = 10). (B) Radioactive RT–PCR of tail
RNA samples obtained frommice treated with saline or 20 mg of
ASO 10–27 at approximately E15. (C) Representative 2-mo-old
mice to show ASO rescue of tail and ear necrosis. The two mice
on the left have normal tails and ears (the one at the far left is
Smn+/; SMN2+/+, and the other one is Smn+/+; SMN2+/+), the
two mice in themiddle are type III SMA mice (Smn/; SMN2+/
+) that were treated as embryos with 20 mg of ASO 10–27, and
the two SMA mice (Smn/; SMN2+/+) on the right received no
treatment. The enlargements show the right ears of one treated
and one untreated mouse.
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shown) mice completely lost their tails by 5–6 wk post-
natally. Some mice treated with 20 mg of ASO eventually
showed tail necrosis starting at ;9–10 wk of age, and the
onset of ear necrosis was generally delayed from 1 mo
to >3 mo postnatally. Mice treated with the lower dose
(10 mg of ASO) also showed a significant delay in the onset
of tail and ear necrosis, but had less phenotypic improve-
ment compared with mice treated with 20 mg of ASO
(Fig. 6A).
To address the possibility that the tail rescue is the
result of ASO leakage from the CSF into tail tissue, as
opposed to rescue of neurons that innervate tail muscles,
we performed RT–PCR analysis with tail RNA samples
isolated from P14 mice (Smn/; SMN2+/+) that had
received an embryonic ICV injection of 20 mg of ASO or
saline vehicle. We initially chose P14 so that we could
compare the tail samples of ASO-treated and control
mice several days before the onset of necrosis. We
observed no differences in SMN2 exon 7 inclusion among
all of these samples, indicating that any potential ASO
leakage from the CNS does not reach a sufficient con-
centration in tail tissue to affect SMN2 splicing (Fig. 6B).
Further examination of tail and other peripheral tissues
(liver and kidney) at various ages from P7 to P30 gave
similar results (data not shown).
Finally, we performed ICV injection of ASO 10–27 in
type III SMA neonates. Each cryoanesthesized P1–P2 pup
received a single injection into a lateral ventricle of 20 mg
of ASO in 2 mL. The onset of tail necrosis was delayed
for ;2 wk, and part of the tail still remained after 2 mo,
whereas the saline and mismatch controls showed the
same phenotype as untreated controls (Supplemental Fig.
S8; data not shown). However, this phenotypic improve-
ment was less pronounced than that in mice treated by
a single embryonic injection. We measured SMN2 exon 7
inclusion with lumbar spinal cord at P7 after a single
neonatal ICV injection of 10 or 20 mg of ASO at P1, and
observed 89% exon 7 inclusion for both doses (data not
shown). Therefore, the reduced phenotypic rescue in
neonate-treated compared with embryonic-treated mice
is a reflection of the timing rather than the extent of
splicing correction.
Discussion
In this study, we directly infused MOE ASO 10–27—
directed against an intronic splicing silencer in human
SMN2 pre-mRNA—into the right lateral ventricle in the
brain of adult transgenic mice. RT–PCR and Western blot-
ting showed efficient SMN2 exon 7 inclusion and a robust
increase in FL hSMN protein in the brain and throughout
the spinal cord. Spinal cord immunostaining showed that
hSMN increased in motor neurons—the cells affected in
SMA patients. Furthermore, by using a single embryonic or
neonatal ICV injection of ASO, we achieved successful
phenotypic rescue in amousemodel of type III SMA. These
data demonstrate that this MOE ASO is a promising drug
candidate to treat SMA.
Tail and ear necrosis is a typical feature in mouse lines
with mild forms of SMA (Hsieh-Li et al. 2000; Tsai et al.
2006; Gavrilina et al. 2008). In addition, various treat-
ments of mice with severe forms of SMA can increase
their survival long enough for the onset of tail and ear
necrosis to be manifested (Narver et al. 2008; Meyer et al.
2009; Foust et al. 2010; Passini et al. 2010; Riessland et al.
2010); for example, Narver et al. (2008) observed tissue
ischemia and progressive necrosis of the tail, the pinnae
of the ears, and sometimes the hind limbs and pelvis in D7
mice treated with trichostatin A (TSA), and they charac-
terized this phenotype histologically as vascular necrosis.
Interestingly, digital necrosis was reported recently as a
clinical feature in two cases of SMA type I children whose
survival had likely been significantly extended through
ventilation and supportive care (Araujo Ade et al. 2009).
These clinical observations defined distal necrosis as a
symptom of SMA, and thus it appears to be a relevant
phenotype for preclinical drug evaluation. Indeed, orally
administered valproic acid, a drug being investigated for
the treatment of SMA, reduces the extent of tail and ear
necrosis in type III SMA C57BL/6J mice (Tsai et al. 2006,
2008). The finding that ICV injection of our lead ASO
efficiently rescued tail and ear necrosis, together with our
observation that splicing correction is limited to the
CNS, suggests that the distal necrosis in type III SMA
mice could be caused by skeletal muscle denervation.
One possibility is that the mild SMN deficiency in the
type III SMAmodel leads to defective motor units mainly
or exclusively in the tail and ears, and the resulting
muscle atrophy in turn leads to local ischemia and vas-
cular necrosis (Narver et al. 2008; Tsai et al. 2008). Sup-
plying the therapeutic ASO to the CNS restored cellular
SMN levels, which in turn might prevent the deteriora-
tion of motor neurons and consequent muscle atrophy.
Another possible scenario is that distal necrosis in SMA
patients and mouse models may result from vascular
perfusion abnormalities related to autonomic nervous
system dysfunction (Arai et al. 2005; Araujo Ade et al.
2009). It remains to be seen whether sympathetic and
parasympathetic nervous system functions are affected
by limiting SMN protein.
We observed that the tails of treated mice were still
shorter than those of mice with Smn+/+ or Smn+/;
SMN2+/+ genotypes. Our interpretation is that, because
SMN is essential for embryonic development, the stage at
which high levels of SMN are restored is probably
important; hence, high levels of SMN beginning at E15,
although clearly beneficial, may not be as effective as
normal levels beginning at E1 (McWhorter et al. 2003). In
addition, the maximal dose given at E15 may gradually
become less effective because of dilution as the embryos
and pups grow. Although tail necrosis was clearly
delayed, it still took place by 2 mo of age; this might be
simply explained by the ASO becoming limiting as the
mice grew, considering that 20 mg is <6% of the total
amount of 350 mg that was required to maintain a high
percentage of SMN2 exon 7 inclusion in the CNS of adult
mice. However, ASO uptake by spinal motor neurons
may be more efficient with embryonic ICV injection than
with adult ICV infusion, because embryos have a more
open ventricular space and fewer brain cells than adults,
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and therefore a higher proportion of ASOmay circulate to
the spinal cord in embryos.
Embryonic ICV injection was more effective than neo-
natal injection in the extent of rescue of tail and ear
necrosis, yet, in both cases, a single ICV injection of $10
mg of ASO led to;90% SMN2 exon 7 inclusion at P7. This
observation suggests that the phenotypic improvement
difference between the two different injection methods is
not just due to a different extent of splicing correction.
Therefore, earlier therapeutic intervention is probably
more effective, as reported in a previous study of TSA
treatment in the D7 mouse model (Narver et al. 2008).
In a recent study, Williams et al. (2009) used a 20mer
29-OMe ASO targeting ISS-N1 to treat severe D7 SMA
mice; they administered five bilateral neonatal ICV in-
jections from P1 to P10, adding up to a total dose of 10 mg.
Williams et al. (2009) reported weight gain and an im-
proved righting response in ASO-treated mice, but they
did not evaluate potential effects on survival. We com-
pared the potencies of our 18mer MOE ASO with the
overlapping 20mer 29-OMe ASO used by Williams et al.
(2009). When the 29-OMe ASO was delivered by ICV
infusion into the adult mouse CNS, we observed no effect
on SMN2 exon 7 inclusion (Supplemental Fig. S6). Fur-
thermore, the 29-OMe ASO—but not theMOEASO—had
a proinflammatory effect in the brain and the spinal cord,
as seen by an increase in AIF1/IBA1, a microglial marker
(Fig. 4), indicating that the 29-OMe ASO may be less well
tolerated when administered into the CNS. Therefore, it
is reasonable to anticipate a much better therapeutic
outcome when the MOE ASO is applied instead with an
appropriate regimen in the D7 mouse model.
The sustained effect of the lead MOE ASO in pro-
moting SMN2 exon 7 splicing in the mouse CNS can be
explained by the high stability of the ASO in CNS tissues.
On the basis of our previous data, particularly the in vitro
splicing data (Hua et al. 2008), we believe that the ASO
exerts its effect mainly, if not exclusively, via blocking
the bipartite hnRNP A1 motif in ISS-N1. Indeed, we
observed that the ASO competes with hnRNP A1 for
binding to the ISS-N1 RNA sequence (data not shown).
However, we did not rule out other epigenetic mecha-
nisms that might also contribute to the persistent ASO
effect in vivo, such as the recently described transcrip-
tional gene silencing-regulated alternative splicing (TGS-
AS) (Allo et al. 2009). However, TGS-AS is elicited by
double-stranded siRNAs, which are assembled into an
RNA-induced silencing complex (RISC), whereas we used
a single-stranded, chemically modified ASO, which does
not load into RISC (Lima et al. 2009). In addition, the
intron preceding exon 7 in SMN2 is long, which is not
typical of characterized TGS-AS substrates. Another for-
mal possibility is that increasing SMN protein concentra-
tion above a certain threshold establishes a regulatory loop
that helps maintain high levels of exon 7 splicing.
In terms of SMA therapy, because the drug will be
administered by an invasive procedure in neonates and
young children, it will be an advantage to have a half-life
long enough to allow infrequent dosing. Our preclinical
data demonstrated that the lead ASO has met such a
criterion. The safety of systemically administered MOE
oligonucleotides in humans has been well characterized,
and no serious side effects have been observed after sys-
temic administration at therapeutically effective doses
(Crooke 2004). The main safety issues are potential off-
target hybridization events and potential chemistry class-
related effects. Sequence analysis revealed that this ASO
has no other perfect targets, and a 1-basemismatch to only
two additional human genes. Given that this oligonucle-
otide design does not cause cleavage of the target RNA, the
potential for adverse effects due to hybridization to non-
targeted RNAs is greatly reduced. Additional preclinical
studies will be required to fully characterize the safety
profile of this ASO in multiple animal species.
The lead ASO already possesses the critical qualities
of a drug to treat SMA. Although the inability of ASOs
to cross the BBB limits the utility of systemic adminis-
tration, well-established implantable catheters and pump
technology can overcome this obstacle. Intrathecal pumps
have been used clinically to deliver drugs to the spinal cord
of patients with debilitating chronic pain or severe spas-
ticity (Belverud et al. 2008), and should be suitable for ASO
delivery. In addition, our experiments in embryonic mice
demonstrate that a bolus injection is also effective. In-
trathecal bolus administration is a well-accepted route for
drug delivery for infants and young children. Progress is
also being made in developing drug carriers to circumvent
the BBB. For example, a nanogel carrier system and a short
modified viral peptide have shown promise in delivering
oligonucleotides through the BBB (Vinogradov et al. 2004;
Kumar et al. 2007). Refinement of such strategies may
ultimately allow direct systemic administration of ASO
for SMA therapy.
Materials and methods
Oligonucleotide synthesis
The synthesis and purification of ASO 10–27 (59-TCACTTTCA
TAATGCTGG-39) and a six-mismatch control (59-TTAGTTTAA
TCACGCTCG-39) 29-O-methoxyethyl-modified oligonucleotides
with phosphorothioate backbone and all 5-methyl cytosines, and
a 29-OMe-modified phosphorothioate oligonucleotide (59-AUUC
ACUUUCAUAAUGCUGG-39) (Singh et al. 2006; Williams et al.
2009) were performed as described (Baker et al. 1997; Hua et al.
2008). The oligonucleotides were dissolved in 0.9% saline.
Animals
All mouse protocols were in accordance with Cold Spring Harbor
Laboratory’s Institutional Animal Care and Use Committee
guidelines. The initial breeding SMA type III model mice were
purchased from Jackson Laboratory, and were originally de-
veloped by Hsieh-Li et al. (2000). We used strain FVB.Cg-
Tg(SMN2)2HungSMN1tm1Hung/J, founder line 2, stock number
005058.
Cranial surgery and ICV infusion
The procedure was based on a protocol used with rats (Smith
et al. 2006). In brief, adultmice 3–4moold, of both sexes, weighing
20–30 g were anesthetized and placed on a digital stereotaxic
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instrument (David Kopf Instruments). A small burr hole at the
surgical site (1.8 mm lateral to the sagittal suture and 0.3 mm
posterior to the bregma suture) was drilled through the skull above
the right lateral ventricle, andwas used to position a cannula (with
a 2.2-mm stylet). The cannula was connected to an Alzet micro-
osmotic pump (model 1007D, Durect Corporation) with a vinyl
catheter. The pump, prefilled with ASO solution (or saline only),
was implanted subcutaneously on the back, and continuously
infused the ASO solution through the cannula into the lateral
ventricle at a rate of 0.5 mL per hour.
Embryonic ICV injection
The procedure was modified from an earlier report (Saito 2006).
In brief, pregnant mice with approximately E15 embryos were
anesthetized, and a 3-cm-long midline incision in the abdomen
was made using scissors. The uterus was pulled out of the
abdominal cavity with ring forceps and kept wet with warm
saline. A glass micropipette was used to deliver ASO solution to
one of the cerebral lateral ventricles of each embryo. Fast Green
FCF (0.01% [w/v]; Sigma-Aldrich) was included in the ASO
solution, so that the shape of both lateral ventricles could be
visualized if the ICV injection was successful. A total of 2 mL of
ASO solution or saline vehicle was injected into each embryo.
After injection, the uterus was placed back into the abdominal
cavity, and the abdominal wall and the skin were closed with
sutures.
Radioactive RT–PCR and real-time RT–PCR
Twenty milligrams of tissue was pulverized in liquid N2 with
mortar and pestle, and homogenized with 1 mL of Trizol
(Invitrogen). Total RNA was isolated according to the manufac-
turer’s directions. One microgram of total RNA was reverse-
transcribed with ImProm-II Reverse Transcriptase (Promega).
Standard amplification and analysis of SMN2 transcripts was
performed as described (Hua et al. 2008). Real-time RT–PCR
(Smith et al. 2006) was performed on an Applied Biosystems
StepOnePlus instrument with an Express One-Step SuperScript
Kit, according to the manufacturer’s instructions. Each reaction
contained 50 ng of total RNAwith 300 nM primer concentration
and 100 nM probe concentration. The probes for detection
of SMN2 transcripts were double-labeled with 59-6FAM and
39-MGBNFQ. Primer/probe set sequences for FL SMN2 tran-
script were forward primer, 59-GCTGATGCTTTGGGAAGTAT
GTTA-39; reverse primer, 59-CACCTTCCTTCTTTTTGATTTT
GTC-39; probe, 59-TACATGAGTGGCTATCATACT-39. Primer/
probe set sequences for D7 SMN2 transcript were forward, 59-TG
GACCACCAATAATTCCCC-39; reverse, 59-ATGCCAGCATTT
CCATATAATAGCC-39; probe, 59-TCCAGATTCTCTTGATGA
TG-39. The primer/probe set sequences for Aif1 were forward,
59-TGGTCCCCCAGCCAAGA-39; reverse, 59-CCCACCGTGT
GACATCCA-39; probe, 59-AGCTATCTCCGAGCTGCCCTGA
TTGG-39. GAPDH mRNA levels were used as an internal ref-
erence for normalization.
Western blotting
Twenty milligrams of tissue was pulverized in liquid N2 and
homogenized in 0.4 mL (liver, kidney, or brain) or 0.2 mL (spinal
cord) of 13 protein sample buffer containing 2% (w/v) SDS, 10%
(v/v) glycerol, 50 mM Tris-HCl (pH 6.8), and 0.1 M DTT. Protein
samples were separated by 12% SDS-PAGE and electroblotted
onto nitrocellulose membranes. The blots were probed with
mAb SMN-KH, mAb anti-SMN SMN-BD purchased from BD
Biosciences, or pAb anti-b-tubulin (GenScript), followed by
secondary IRDye 800CW-conjugated goat anti-mouse or anti-
rabbit antibody. Protein signals were detected with an Odyssey
instrument (LI-COR Biosciences). For Western blotting in the
Supplemental Material, chemiluminescence detection was used
(see Supplemental Fig. S1).
Immunostaining
Spinal cord was fixed with 4% (v/v) formaldehyde in phosphate-
buffered saline (PBS) overnight. ASO and SMN immunohisto-
chemistry was performed as described (Butler et al. 2000). For
SMN and ChAT immunofluorescence, fixed tissue was soaked in
30% (w/v) sucrose overnight at 4°C and embedded in frozen
medium. Ten-micron sections were cut and mounted on Super-
frost slides (Fisher Scientific). After blocking with 5% (v/v) goat
serum and 0.2% (v/v) Triton X-100 in PBS, tissue was incubated
with SMN-KH and rabbit anti-ChAT pAb (Abcam), followed by
goat anti-mouse Alexa fluor 488 and goat anti-rabbit Alexa fluor
568 secondary antibodies (Invitrogen). Confocal immunofluores-
cence images were acquired with an UltraView Vox confocal
imaging system (Perkin Elmer) and a Nikon Ti-E inverted micro-
scope (Nikon Instruments) equipped with a 203 or 403/0.75 NA
objective lens and an Orca ER CCD camera (Hamamatsu Pho-
tonics).
Statistical analyses
We determined statistical significance by two-tailed Student’s
t-tests.
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